| Title |
Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, November 2010
|
| DOI | 10.1007/s00280-010-1506-7 |
| Pubmed ID | |
| Authors |
M. Tanioka, H. Nokihara, N. Yamamoto, Y. Yamada, K. Yamada, Y. Goto, T. Fujimoto, R. Sekiguchi, K. Uenaka, S. Callies, T. Tamura |
| Abstract |
LY2181308 is an antisense oligonucleotide that complementarily binds to survivin mRNA and inhibits its expression in tumor tissue. This phase I dose escalation study evaluated the tolerability, pharmacokinetics, and anticancer activity of LY2181308 in Japanese. |
Mendeley readers
The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 2 | 5% |
| United States | 1 | 3% |
| Unknown | 34 | 92% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 8 | 22% |
| Researcher | 7 | 19% |
| Student > Master | 4 | 11% |
| Student > Bachelor | 3 | 8% |
| Professor > Associate Professor | 3 | 8% |
| Other | 6 | 16% |
| Unknown | 6 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 27% |
| Biochemistry, Genetics and Molecular Biology | 7 | 19% |
| Agricultural and Biological Sciences | 3 | 8% |
| Chemistry | 3 | 8% |
| Unspecified | 2 | 5% |
| Other | 4 | 11% |
| Unknown | 8 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 September 2011.
All research outputs
#7,856,604
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#688
of 2,501 outputs
Outputs of similar age
#32,617
of 89,479 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#5
of 19 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 32nd percentile – i.e., 32% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 89,479 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one is in the 10th percentile – i.e., 10% of its contemporaries scored the same or lower than it.